Terms: = Ovarian cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568
11 results:
1. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.
Bondeson DP; Paolella BR; Asfaw A; Rothberg MV; Skipper TA; Langan C; Mesa G; Gonzalez A; Surface LE; Ito K; Kazachkova M; Colgan WN; Warren A; Dempster JM; Krill-Burger JM; Ericsson M; Tang AA; Fung I; Chambers ES; Abdusamad M; Dumont N; Doench JG; Piccioni F; Root DE; Boehm J; Hahn WC; Mannstadt M; McFarland JM; Vazquez F; Golub TR
Nat Cancer; 2022 Jun; 3(6):681-695. PubMed ID: 35437317
[TBL] [Abstract] [Full Text] [Related]
2. Characterization of
Vlasenkova R; Nurgalieva A; Akberova N; Bogdanov M; Kiyamova R
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944522
[TBL] [Abstract] [Full Text] [Related]
3. The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen slc34a2/NaPi2b.
Bodyak ND; Mosher R; Yurkovetskiy AV; Yin M; Bu C; Conlon PR; Demady DR; DeVit MJ; Gumerov DR; Gurijala VR; Lee W; McGillicuddy D; Park PU; Poling LL; Protopova M; Qin L; Stevenson CA; Ter-Ovanesyan E; Uttard A; Xiao D; Xu J; Xu L; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):896-905. PubMed ID: 33722858
[TBL] [Abstract] [Full Text] [Related]
4. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract] [Full Text] [Related]
5. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.
Liu L; Yang Y; Zhou X; Yan X; Wu Z
Biomed Pharmacother; 2018 Mar; 99():645-654. PubMed ID: 29653487
[TBL] [Abstract] [Full Text] [Related]
6. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
7. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical Development of an Anti-NaPi2b (slc34a2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and ovarian cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract] [Full Text] [Related]
9. Quantitative analysis of slc34a2 expression in different types of ovarian tumors.
Shyian M; Gryshkova V; Kostianets O; Gorshkov V; Gogolev Y; Goncharuk I; Nespryadko S; Vorobjova L; Filonenko V; Kiyamova R
Exp Oncol; 2011 Jun; 33(2):94-8. PubMed ID: 21716206
[TBL] [Abstract] [Full Text] [Related]
10. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (slc34a2) in human carcinomas.
Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression.
Rangel LB; Sherman-Baust CA; Wernyj RP; Schwartz DR; Cho KR; Morin PJ
Oncogene; 2003 Oct; 22(46):7225-32. PubMed ID: 14562052
[TBL] [Abstract] [Full Text] [Related]
